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Infection remains the principal cause of morbidity and mortality in febrile neutropenic episodes in cancer patients. During 
the 1960s and 1970s, infection was responsible for 80% of deaths in patients with hematological malignancy, but 
observations from clinical trials completed by the International Antimicrobial Therapy Cooperative Group of the European 
Organisation for Research and Treatment of Cancer (IATCG-EORTC) show that in recent years, mortality rates due to 
infection have fallen to  approximately 3%, in patients undergoing active treatment of the malignancy. For patients 
considered beyond active treatment, figures are much higher. This improvement is undoubtedly due to the introduction 
and use of empirical therapy in the early 1970s. The rationale for developing the concept of empirical therapy was based 
on the fact that blood culture results may not be available for several days, with disastrous consequences for treatment of 
a rapidly progressing infection. Therefore, antibiotics are given to febrile neutropenic cancer patients without definitive 
microbiological proof of infection. 
Many studies on empirical therapy have investigated combinations of agents, such as a 0-lactam plus an 
aminoglycoside. Such antibiotic combinations offer broad-spectrum antibacterial coverage and have been shown to 
provide synergistic bactericidal effects against Gram-negative pathogens in vitro. However, in recent trials on the 
comparison between mono- and combination therapy the time to defervescence did not significantly differ, suggesting 
that a more synergistic bactericidal effect, as observed in vitro with combinations, did not have a measurable counterpart 
in vivo on fever duration. Combinations may also reduce the emergence of resistant isolates that are observed when 
certain 0-lactam antibiotics are used alone. Aminoglycoside-containing regimens are, however, associated with ototoxicity 
and nephrotoxicity. In efforts to  circumvent this, some investigators have used double p-lactam combinations but, recently, 
monotherapy with newer extended-spectrum agents such as the carbapenems, third- and fourth-generation 
cephalosporins and fluoroquinolones have become increasingly studied and used as standard empirical therapy. 
The criteria for evaluating the response to empirical antibiotic treatment in febrile neutropenia have evolved from a 
number of clinical trials. These studies have indicated that age, the duration of neutropenia, the nature of the underlying 
disease, the causative pathogen, the availability of new effective drugs, and the chosen end point all have a profound 
influence on response rates. Moreover, a clear understanding of the objectives and design of trials is of paramount 
importance in interpretation of the results and comparison of data from different trials. Recently, there has been a move 
towards more rational use of antibiotics with the identification of patient subgroups at lower risk of unfavourable outcome, 
who might be treated more appropriately with less aggressive, tailored, empirical therapy. This review examines the 
effectiveness of empirical therapy in studies from different centers during the last 20 years, and looks towards possib 
for modification of treatment strategies in the future, to combat emergence of new pathogens and the development of 
resistance in established pathogens. 
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prolonged periods of time [2,3]. This is defined as 
profound prolonged neutropenia. This is in contrast 
to patients with chronic severe neutropenia, such as in 
Kostmann’s syndrome, where the neutropenia is chronic. 
Patients with granulocyte counts of between 500 and 
1,000 celldmm3, which are expected to decrease within 
hours, are eligble for inclusion in most trials, since a rapid 
decline is often associated with infection. Duration of 
neutropenia, at < 500 cells/mm3 or < 100 cells/mm3 in 
profoundly neutropenic patients, is a very important 
parameter in classifying patients into subgroups for 
evaluation of response to empirical therapy. Short 
neutropenia, of less than one week’s duration; is mainly 
associated with the treatment of solid tumors, whereas 
neutropenia of more than two weeks’ duration is 
generally associated with the treatment of hematological 
malignancies. 
DEFINITION OF RESPONSE RATES 
Cancer patients with profound neutropenia 
(< 100 cells/mm3) present some of the most stringent 
conditions for testing empirical antibiotic regimens. 
Optimal management of these patients remains 
controversial, in particular, with regard to whether 
they should receive a p-lactam alone o r  in 
combination with an aminoglycoside (Table 1). 
Controversies regarding the definition of response 
rates and the appropriate management of infection can 
be highlighted with the example of two studies, 
from the National Cancer Institute (NCI) and the 
IATCG-EORTC. In a large study at the National 
Cancer Institute (NCI) in the USA [4], cefiazidime 
monotherapy was compared with triple therapy 
(cephalothin, gentamicin, carbenicillin) in the initial 
management of fever and neutropenia in 550 
evaluable patients with cancer. Response rates were 
similar for both regimens (77% and 78%) in patients 
with unexplained fever, but the majority of cases of 
documented infection required additional antimicrobial 
treatment such as an aminoglycoside or glycopeptide. 
The investigators concluded, however, that single- 
agent therapy was as safe and effective as standard 
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combination treatment, provided patients with 
documented infection or protracted neutropenia were 
given additional treatment. 
Another strategy of combination therapy was tested 
in an equally large study by the IATCG-EORTC, in 
which a combination of cefiazidime plus a long course 
(9 days) of amikacin was compared with ceftazidime 
plus a short course (3 days) of amikacin in 872 profoundly 
neutropenic patients [5]. The results showed that 
there was no significant difference in response rate to 
either the short or long course of amikacin in patients 
presenting with fever of unknown orign (76% and 8196, 
respectively) and clinically documented infection 
(68% and 66%, respectively). However, the subgroup 
of 129 patients with microbiologically documented, 
single-organism, Gram-negative bacteremia, responded 
significantly more to long-course amikacin therapy 
(81% response rate) than to short-course treatment 
(48%). A more marked difference was evident in 
bacteremic patients with persistent neutropenia, of 
whom just 6% responded to ceftazidime plus short- 
course amikacin compared with 50% responding 
successfully to long-course therapy. These outcomes 
suggested that every patient should receive combination 
therapy, and that re-evaluation could be done by the 
third day. The combination could be stopped if 
microbiological results were negative, but a full course 
of combination therapy should be continued in 
bacteremic patients, particularly in those patients with 
profound neutropenia. There was no evidence of 
reduced nephrotoxicity in patients receiving the 
shorter amikacin regmen. 
The apparent difference emerging from these two 
studies can be partially explained by considering the 
definitions of success and failure. The IATCG- 
E O R T C  defined success as resolution of fever and 
signs of infection achieved by the empirical regimen 
tested; any modification to the regimen was classified 
as a failure. In contrast, the NCI considered that any 
recovery from infection during febrile neutropenia 
was successful, irrespective of modification to the 
regimen. Only death from infection was judged to 
represent failure. In order to reconcile these 
Table 1 Possible choices for empirical therapy of fever in neutropenic patients 
~~~ ~ ~ 
Combination Therapy Monotherapy 
p-lactam + aniinoglycoside 
p-lactam + fluoroquinolone 
Carbapenem 
Third- or fourth-gencration cephalosporin 
Anti-pseudomonal penicillin + p-lactamase inhibitor 
Fluoroquinolone with enhanced Gram +ve activity 
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differences in definition, a consensus conference of 
the Immunocompromised Host Society (IHS) was 
convened in the early 1990s. It was agreed that in 
future studies, success should be defined as resolution 
of fever and signs of infection, with no  recurrence, 
and if modification to the initial antimicrobial 
regimen (including antifungal, antibacterial, antiviral 
and antiparasitic agents) was required, t.his was to be 
classified as failure (Table 2) [6]. 
Other factors also contributed to the apparently 
contradictory outcomes. The IATCG-EORTC study 
recruited adults only, whereas a large proportion of 
the patients in the NCI  study were children, who are 
known to be less at risk from severe infection than 
adults. Iniportantly, the majority of patients in the 
IATCG-EORTC study were leukeimics with a 
duration of neutropenia of between 15-20 days, but 
most of the underlying diseases in the NCI study were 
solid tumors and the duration of neutropenia was 
usually < 10 days. This difference alone would influence 
the S L I C C ~ S S  of any empirical therapy strategy. 
When considering monotherapy or combination 
therapy it is iniportaiit to consider the definition of 
failure. The  choice between monotherapy and 
combination therapy will also be influenced by the 
risk of acquiring severe infections. Patients at low risk, 
such as those with solid tumors and a :short duration 
of neutropenia, may be adequately treated with 
monotherapy. Combination therapy can be considered 
for adults with hematological malignancies and with a 
long duration of neutropenia. An acceptable alternative 
to combination therapy could be initial monotherapy 
with a broad-spectrum antibiotic, with treatment 
modification as dictated by clinical and microbiological 
documentation at 72-96 hours of therapy. 
EPIDEMIOLOGY OF FEBRILE NEUTROPENIA 
Gram-positive bacteria are now the predominant cause 
of infections in granulocytopenic canccr patients [7].  
The most h-equently isolated pathogens are staphylococci 
(particularly coagulase-negative strains) and alpha- 
hemolytic streptococci (Figure 1). Treatment of these 
infections is further complicated by the increasing 
incidence of drug-resistant organisms, particularly with 
respect to Stuphylococcur uureus, coagulase-negative 
staphylococci (CNS) and also streptococci and 
enterococci. The increase in incidence of Gram-positive 
bacteria has several possible causes. These include 
mucosal and skin damage, an increase in the use of 
indwelling catheters, and an increase in the use of 
prophylactic agents such as the fluoroquinolones. Perhaps 
the most important factor is severe mucositis that is 
observed following the increased use of Ara-C, VP16 
and anthracyclines in cancer patients, which allows free 
access of mouth flora into the blood stream (Table 3). 
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Figure 1 Trends in single organism bactereniia in eight 
EOKTC trials over a 20-year period. 
Table 2 Criteria for evaluation of empirical antibiotic treatment in neutropenia 
Success Failure 
Resolution of fever and signs of infection 
N o  recurrence for 2 1 week after cliscontinuation 
Change in initial antimicrobial regimen (including addition of 
antifungal, antibacterial, antiviral or an tiparasitic agent) 
Non-evaluable (FUO only): no response to initial antilmcrobial 
regimen leading to change in antimicrobial treatment Initial response but regimen modified: eradication 
of initial pathogen, but a second infection/fever 
develops requiring another antimicrobial agent 
IHS consensuP conference [6]. With permission ofJ  Infect Dis 
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Table 3 Risk factors for Gram-positive infections in the neutropenic host 
Predisposing factors Infecting pathogens 
Skin damage (punctures) Staphylococci, Corynebacten’um spp 
Foreign bodies (catheters) Staphylococci, Covynebactenlrm JK 
Mucosal damage (chemotherapy, 
radiation therapy, viral infection) 
a-hemolytic viridans streptococci, 
anaerobes, staphylococci 
Endogenous flora Coagulase-negative staphylococci, 
enterococci, Gram-positive anaerobes 
Antimicrobial prophylaxis 
0 Non-absorbable antimicrobials Coagulase-negative staphylococci, 
0 Fluoroquinolones a-hemolytic viridans streptococci 
Viridans group streptococci have become a major 
concern in  neutropenic patients undergoing 
chemotherapeutic treatment, and are responsible for 
up to 39% of bacteremic cases and 22% of all infections 
[8]. A survey of data from three IATCG-EORTC 
trials, together with the results from trials conducted 
in Nebraska, USA and Lausanne, Switzerland, has 
established that viridans streptococci are now a major 
cause of bacteremia during neutropenia, with a 
mortality rate of 10-15% [8,9]. This heterogeneous 
group of organisms forms part of the normal 
oropharyngeal flora. Isolates recovered from 
bacteremic neutropenic patients have the same 
ribotype as those found in the oral flora [9], 
demonstrating that damaged oral mucosa, resulting 
from mucositis, induced by cytosine arabinoside 
chemotherapy, for example, may be a portal of entry 
for streptococci found in blood cultures. Other risks 
include severe neutropenia, prophylaxis with co- 
trimoxazole or quinolones and strong colonization of 
patients [8] (Table 3) .  The species identified most 
frequently are S. mitis, S. oralis and S .  ranguis. Oral 
administration of penicillin as prophylaxis can 
decrease the incidence of viridans streptococcal 
bacteremia [lo]. This is now followed by the fact that 
isolates are increasingly displaying high-level 
resistance to penicillin (MIC 2 2 mg/L), which 
complicates subsequent management [lo]. 
While Gram-positive organisms have increased, 
there has been a corresponding reduction in the 
number of Gram-negative isolates in febrile neutropenic 
patients (Figure 1). Gram-negative pathogens are 
mainly Escherichia coli and Klebsiella spp. with 
Aeudomonas aeruginosa present in about 5-10%. 
However, considerable variation may exist between 
geographically defined areas. Many patients have 
repeated courses of antibiotic therapy and consequently 
suffer bacteremia from organisms resistant to multiple, 
broad-spectrum antibiotics such as Enterobacter spp. 
[I 11. Gram-negative bacteremia was a leading cause of 
death in febrile neutropenic patients accounting for 
approximately 30% of deaths by infection in some 
studies [ 121. However, recently, mortality from 
Gram-negative bacteremia was found to be similar to 
that from Gram-positive bacteremia at approximately 
10% (Table 4) [13-151. Perhaps the most feared 
among the cases of bacteremia today are the 
streptococci, as suggested by a meta-analysis of eight 
Table 4 Comparison of 30-day mortality rates between Gram-positive and Gram-negative infections in neutropenic patients 
Overall Gram-positive bacteremia Gram-negative bacteremia 
Number of patients 2567 
- survived (%) 91.9 
- died of primary infection (%) 1.4 
- d e d  of further infection (“9) 1.3 
- died (%) 8.1 
362 
89.2 
10.8 
3.0 
1.1 
171 
89.5 
10.5 
3.5 
1.2 
Data from EORTC mals VIII, IX and XI [13-15). 
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different studies, in which an average mortality rate of 
17% was observed in cases of streptococcal bacteremia 
(Table 5 )  [8,16-221. 
MANAGEMENT OF FEBRILE NEUTROPENIA 
As infection is a major cause of death in the 
iinmuiiocompromised host [12,23-261 antimicrobial 
therapy must be initiated as soon as infection is suspected 
in neutropenic patients [27,28]. Patients with neutropenia 
of < 10 days duration and no clinical site of infection 
may be treated satisfactorily with single-agent antibiotic 
therapy. This, together with the possibility of managmg 
these individuals as outpatients, is one of several options 
now being explored for simplification of empirical 
therapy in low-risk cancer patients (Table 6). 
Problems remain with the treatment of patients 
with longer lasting neutropenia, of more than two 
weeks’ duration. Response rates to standard 
ceftazidime/amikacin combination in the most recent 
IATCG-EORTC studies have declined in patients 
with documented bacteremia (Table 7) [13,14]. 
Indeed, the shifting spectrum of causative pathogens 
in bacteremia has had profound consequences for the 
effectiveness of empirical treatment in neutropenic 
patients. The response rates, as measured by the 
success of empirical therapy, to a variety of 
aminoglycoside@-lactam combination therapies have 
Table 5 Streptococcal bacteremia (and related mortality) in eight studies in nentropenic cancer patients 
Authors Year Streptococcal bacteremia Death? 96 Rcf 
~ ~~ 
Cohen 
Brown 
Menichetti 
Micozzi 
GIMEMA 
Elting 
Awada 
Bochud 
1983 
1984 
1987 
1990 
1990 
1991 
1992 
1994 
10 
26 
10 
21 
25 
46 
78 
26 
1 
2 
3 
1 
3 
11 
20 
1 
16 
17 
18 
19 
2 0 
21 
22 
8 
Total 242 42 17 
Table 6 Options for simplified empirical treatment for low-risk febrile neutropenic cancer patients 
0 Single daily dose iv combination therapy 
0 Single-agent iv therapy 
0 Outpatient iv therapy 
0 Sequential iv - oral therapy 
0 Initial oral therapy 
Table 7 Kesponse rates for ceftazidime-amikacin empirical therapy in neutropenic patients with microbiologcally 
documented infection 
EORTC 
Trial VIII 
(1 988-1 9 90) 
Tnal IX 
(1 99 1 -1 ‘192) 
Microbiologically documentcd infection 59/104 (57%) 43/112 (38%) 
with bactcremia: 46/90 (51%) 35/101 (35%) 
Gram-negative 19/27 (70%) 18/29 (62%) 
Polymicrobid 5/13 (39%) 3/ 1 6 (1 9u/) 
Gram-positive 22/50 (44%) 14/56 (25%) 
Data adapted from the E O R T C  trials VIII, IX [13,14]. 
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declined over the last 20 years, 1Eom 71% for cephalothin 
or carbenicillin combined with various aminoglycosides 
in the first IATCG-EORTC trial (1973-1976) to 
25% for ceftazidime combined with amikacin in the 
ninth trial (1991-1992) (Table 8) [13,14,29-311. In 
these studies, failure was defined as a change to empirical 
therapy, therefore the decline probably reflects the 
inadequate cover against Gram-positive pathogens. 
To  address this problem, a trial was designed by 
IATCG-EORTC in which vancomycin was added to 
the standard combination of ceftazidime plus amikacin 
as initial empirical treatment of febrile neutropenic 
patients [32]. Gram-positive bacteremia was present in 
63% of 213 single-organism bacteremias. In these 
cases, there was a significantly lower incidence of 
treatment failures in the group receiving triple therapy 
(28%) than in the group receiving standard treatment. 
Failure was mainly attributed to the necessary addition 
of vancomycin to the ceftazidime/amikacin arm, when 
patients had not defervesced by 48 hours. Interestingly, 
the time to defervescence in these patients was 
identical, irrespective of whether vancomycin was 
instituted, thus questioning the need for triple 
therapy. The fact that the median time to 
defervescence is about 5 days [33], even when patients 
receive entirely adequate antibiotic treatment with full 
microbiological coverage, must be taken into 
consideration. T o  determine the need for including 
vancomycin in the treatment of patients who have not 
defervesced by 48-72h, a double-blind, placebo- 
controlled trial is currently underway, in which 
patients with persistent fever will be randomized to 
receive either vancomycin or placebo. 
T h e  use of a glycopeptide (vancomycin or  
teicoplanin) combined with an aminoglycoside/ 
p-lactam regimen as empirical therapy for fever is 
warranted only in patients with suspected methicillin- 
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resistant S. aureus (MRSA) or CNS infections, as well as 
susceptible Gram-positive infections not responding 
to initial therapy [32,34]. These infections tend to occur 
more often in patients with indwelling central venous 
catheters, although these devices do not constitute the 
only causative factor. In centers where most bloodstream 
infections are caused by P-lactam-resistant Gram-positive 
bacteria, the glycopeptides could be considered in the 
initial empirical regimen [32]. However, because of their 
potential toxicity (especially when combined with an 
arninoglycoside) and their unknown cost efficiency, 
including glycopeptides in the first line empirical 
treatment of all febrile neutropenic patients is 
controversal. Moreover, the potential for the widespread 
use of glycopeptides in engendering resistance, especially 
in enterococci, should encourage any clinical trials 
aiming to find strategies to reduce the use of 
glycopeptides to strict indications. 
The addition of the P-lactamase inhibitor tazobactam 
extends the spectrum of the ureidopenicillin piperacillin 
to include P-lactamase-producing organisms. In vitro 
studies showed that piperacillin-tazobactam had 
activity comparable with that of ceftazidime against 
Gram-negative bacteria isolated from bacteremic 
granulocytopenic cancer patients and was superior to 
ceftazidime against S .  aureus and viridans streptococci 
[35], suggesting that piperacilLin-tazobactam may have 
a role in the empirical treatment of febrile neutropenic 
infection. 
COMBINATION THERAPY VERSUS MONOTHERAPY 
Epidemiological changes have prompted the need for 
empirical combinations that include drugs to cover 
Gram-positive pathogens. However, efforts are being 
made to replace empirical combination therapy with 
monotherapy for various reasons, including toxicity 
Table 8 Clinical response rates to empirical combination treatment of Gram-positive infections i n  neutropenic patients in  6 
EORTC trials over 20 years 
Trial Date Aminoglycoside plus: Response rate (%) Reference 
I 1973-1976 Cephalothin or carbenicillin 
I1 1977-1 980 Carbenicillin k cefazolin 
I11 1980-1983 Ticarcillin 
Cefotaxime 
Azlocillin 
IV 1983-1985 Azlocillin 
Ceftazidime 
VIII 398d1990 Ceftazidime 
IX 1991-1992 Ceftazidime 
71 
73 
32 
43 
67 
51 
46 
44 
25 
29 
30 
31 
5 
13 
14 
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and economy. Potential candidates for monotherapy 
are outlined in Table 1. There is potentially a higher risk 
of selection of resistant mutants with certain p-lactams 
being used as monotherapy than with combination 
therapy 15,361, although thn is controvt:sial in non- 
neutropenic patients, and has not been observed in the 
most recent well designed trials [14]. 
The carbapenems are good candidates for 
monotherapy because of their broad-spectrum of 
activity. Potential canddates include imipenem-cilastatin 
and meropenem. Monotherapy with iinipenem was 
compared with ceftazidime in the management of 
fever and neutropenia in 399 patients with solid tumors, 
leukemias or lymphomas [37]. Both agents were 
effective according to the NCI criteria for response, with 
an overall success rate of 98%, although addition of other 
antibiotics was necessary in half of all episodes. Imipenem 
therapy, at the daily dose of 4 x 1 g was, however, 
associated with significantly greater gastrointestinal 
toxicity and sometimes seizures, and did not decrease the 
overall need for antibiotic modifications, despite its 
broad spectrum of activity. The newer carbapeneni, 
meropenem seems to be a safer and less toxic alternative. 
In a recent study, meropenem was recently evaluated as 
monotherapy in comparison with ceftazidime/amikacin, 
as empirical treatment in severely-ill, high-risk cancer 
patients with long duration of iieutropeiiia (1 8-20 days) 
1141. Meropenem was as effective as thsc combination 
with 56% and 52% of patients responding successfully 
to treatment. respectively. However, there was a 
non-significant trend towards time to defervescence 
being shorter in patients receiving; meropenem 
than cefiazidime plus amikacin (p = 0.07), while in 
the combination arm more renal toxicity was 
encountered. In another randomized multicenter trial, 
nieropenem monotherapy  was compared to 
ceftazidime monotherapy in patients with profound 
and prolonged neutropenia [38]. By the end of the 
treatment courses, 44% of febrile episodes had responded 
to meropenem, compared with 41% to ceftazidime. 
Failure as defined by the addition of other antibacterial 
agents occurred in 53% of ceftazidime treated episodes 
versus 41% with meropenem. All patients survived the 
first 3 days of treatment. Thus, monotherapy prevented 
early death due to infection, while at tlie same time 
avoiding initial combinations with, for example, 
aminoglycosides or glycopeptides in over 40% of patients. 
An alternative agent to be considered for 
monotherapy is piperacivin-tazobactam. An initial study 
has demonstrated similar efficacy fcir piperacillin- 
ta;.obactam in combination with amikacin compared 
to a combination of ceftazidime plus a:mikacin [ 151. 
T h e  third-generation cephalosporins have 
demonstrated significant clinical efficacy over thc years, 
but the effectiveness of newer agents such as ceftazidime 
against Gram-positive organisms is suboptimal, 
compared with older agents, which include cefotaxime 
or cefiriaxone. Moreover, their activity against Gram- 
negative species has been compromized by tlie enzyme 
of derepressed, chromosomally-mediated p-lactamases 
in some bacterial species arid by mutation in plasmid- 
encoded p-lactamases in others. Development of 
resistance may be particularly devastating in neutropenic 
patients. Several cases have been reported of 
breakthrough bacteremia with multiple-resistant 
Enterobarfev spp. in febrile, neutropenic, cancer patients 
receiving broad-spectrum cephalosporins as monotherapy. 
Indeed, Enterobactev bacteremia resistant to ceftazidime 
has emerged during therapy with this agent [I 11. 
The fourth-generation cephalosporins have good 
activity against streptococci, including viridaiis group 
streptococci, and methicillin-susceptible staphylococci, 
all of which are pathogens most coninionly isolated 
in bacteremic febrile neutropenic patients [38,39]. 
Moreover, they provide increased coverage against 
mutant strains of Enterobacteriaceae and P.  aeruginosa 
producing derepressed AmpC p-lactamase. The C-3' 
quaternary ammonium cephenis, cefpirome and 
cefepime, possess enhanced activity compared with other 
cephalosporins and offer advantages against resistant 
mutants of certain Gram-negative species, by virtue of 
having a low affinity for chromosomal 0-lactamases [39]. 
Moreover, they are among the most effective p-lactams 
against strains of Streptococcus pneumoniae displaying 
intermediate- and high-level resistance to penicillin 
[40-421. 
The antibacterial activity of cefepime has recently 
been reviewed [43]. In a pilot, open, non-comparative 
study, empirical cefepime monotherapy was judged to 
be safe and effective in the treatment of febrile episodes 
in neutropenic patients [44]. In a randomized study, 
the Combination of cefepime plus arriikacin showed 
equivalent efficacy to cefiazidime plus amikacin in 
febrile neutropenic patients [45]. 
In an initial trial, cefpirome was as effective as 
ceftazidime in the empirical treatment of febrile 
episodes in patients with neutropenia 1461. A total 
of 32% of patients in the cefpirome and 35% in 
the ceftazidime treatment groups remained on 
monotherapy, whilst 32% and 33% respectively, 
required the addition of concomitant antibiotics or 
the initiation of new antibacterial treatments. 
Growth factors 
Only a few randomized studies on the use of colony 
stimulating factor (CSF) as adjuncts to empiric antibiotic 
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treatment have been published [47,48]. Both granulocyte 
(G-) CSF and granulocyte-macrophage CSF, when 
initiated at the start of febrile neutropenia, can 
significantly accelerate neutrophil recovery and 
diminish the duration of fever and febrile neutropenia. 
In some trials this has led to a diminished hospital stay, 
fever days on antibiotics, and decreased need for empiric 
amphotericin B. Adjunctive use of CSFs is considered 
to be especially useful in those patients at highest risk 
i.e. with very severe neutropenia (< 0.1 x 1O’/L) or 
protracted neutropenia (> 10 days), after bone marrow 
transplantation or with exhausted marrow reserves after 
multiple chemotherapy cycles. The benefit of G-CSF 
is more pronounced in microbiologically proven 
infections than in fever of unknown origin. 
CONCLUSION 
Combinations of third-generation cephalosporins and 
aminoglycosides was, until now the standard therapy 
for empirical treatment of febnle episodes in neutropenic 
patients. This approach has provided optimal coverage 
against Gram-negative bacteria. However, more 
recently, the prevalence of Gram-positive bacteria has 
increased, particularly CNS and viridans streptococci. 
In response to this, vancomycin has often been 
used empirically in combination with the broad- 
spectrum antibiotics. However, this regimen has not 
improved morbidity or mortality nor reduced time 
to defervescence. Alternatives to third-generation 
cephalosporins should be a carbapenem, piperacillin- 
tazobactam or a fourth-generation cephalosporin. Due 
to variations in geographically defined areas, the 
epidemiology of resistance in a given center is an 
important parameter to consider for choosing the 
best regmen. Recent clinical trials in febrile neutropenic 
patients support that fourth-generation cephalosporins 
have now to be considered as first line armamentarium 
in this setting and are at least as effective as ceftazidime. 
Moreover, their specific activity against Gram-positive 
pathogens fully support their empirical use, especially 
in patients at high risk for streptococcal bacteremia 
whose frequency is increasing in neutropenic patients. 
These properties are also the rationale to design 
clinical trials aiming to decrease the empirical use of 
glycopeptides. Such trials should be encouraged. 
DISCUSSION 
Prof. W. Wilson: This treatment strategy is similar to 
the antibiotic prescribing policy in many institutions 
in the USA. Most hospitals would not recommend 
vancomycin in the initial treatment regimen. The 
recommendations of monotherapy are very consistent 
with many institutions in the USA. A fourth-generation 
cephalosporin, cefpirome and cefepime would 
provide good Gram-negative activity and in addition, 
good Gram-positive activity, an advantage over 
ceftazidime. Monotherapy with the fourth-generation 
cephalosporins would be an attractive alternative to 
ceftazidime as initial therapy of febrile neutropenic 
patients, even though ceftazidime is still widely used 
for monotherapy in the USA. An alternative to this 
regimen would be monotherapy with a carbapenem. 
Prof. M. Glauser: Vancomycin is not recommended 
in the initial treatment regimens for reasons of 
toxicity, and because of the problems of the 
emergence of vancomycin-resistant microorganisms. 
Prof. P. Martino: Many investigators add vancomycin 
in the initial regimen because of the risk of 
staphylococcal infections. There are several studies 
comparing monotherapy versus combination therapy, 
but the majority of these have compared monotherapy 
with a combination of different drugs. A very large 
study from Bodey et al. compared the activity of 
ceftazidime alone, ceftazidime/amikacin, imipenem, 
and imipenem/amikacin. However, no studies have 
addressed whether combination therapy with amikacin 
was necessary in this category of patients. 
GIMEMA is planning a double-blind study in Italy, 
comparing piperacillin-tazobactam plus amikacin 
versus piperacillin-tazobactam plus placebo. This study 
should address the need of combination therapy with 
an aminoglycoside. Vancomycin will also be included 
in the treatment regimen. 
Prof. M. Glauser: The next trial of the IATCG of 
the E O R T C  will initiate empiric monotherapy with 
piperacillin-tazobactam. Patients with Gram-positive 
infections or without documented infections (FUOs 
who remain febrile after 3 days) will be randomized 
blindly to receive vancomycin or placebo. Indeed, a 
significant proportion of patients (about 60%) stdl remain 
febrile at 3 days and this study should address the 
question ofwhether vancomycin is useful at this stage. 
Prof. W. Wilson: Would amphotericin B be 
administered if the patients were still febrile after this 
period of time? 
Prof. M. Glauser: Amphotericin B would usually be 
administered if the patients were still febrile after a period 
of 6 days, but in centers where Aspergillus is endemic, 
amphotericin B would be administered earlier. 
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